DARE vs. ACXP, VIRX, THTX, NRXP, SPRB, ENLV, IPA, FBIO, APRE, and ACST
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Acurx Pharmaceuticals (ACXP), Viracta Therapeutics (VIRX), Theratechnologies (THTX), NRx Pharmaceuticals (NRXP), Spruce Biosciences (SPRB), Enlivex Therapeutics (ENLV), ImmunoPrecise Antibodies (IPA), Fortress Biotech (FBIO), Aprea Therapeutics (APRE), and Acasti Pharma (ACST). These companies are all part of the "pharmaceutical preparations" industry.
Daré Bioscience (NASDAQ:DARE) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.
In the previous week, Daré Bioscience had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 6 mentions for Daré Bioscience and 4 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.69 beat Daré Bioscience's score of 0.26 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.
Daré Bioscience has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.79, indicating that its stock price is 279% less volatile than the S&P 500.
Daré Bioscience received 342 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 90.91% of users gave Acurx Pharmaceuticals an outperform vote while only 73.18% of users gave Daré Bioscience an outperform vote.
6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 5.3% of Daré Bioscience shares are held by insiders. Comparatively, 35.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Acurx Pharmaceuticals has lower revenue, but higher earnings than Daré Bioscience. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.
Acurx Pharmaceuticals' return on equity of -289.69% beat Daré Bioscience's return on equity.
Daré Bioscience presently has a consensus price target of $6.00, suggesting a potential upside of 1,832.37%. Acurx Pharmaceuticals has a consensus price target of $12.00, suggesting a potential upside of 491.13%. Given Daré Bioscience's higher probable upside, equities analysts plainly believe Daré Bioscience is more favorable than Acurx Pharmaceuticals.
Summary
Daré Bioscience beats Acurx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
